Malignant Mesothelioma Research

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
  • Immune Depletion to Enhance Immunotoxin Therapy

    In this clinical trial, patients with advanced mesothelioma who have not benefited from previous chemotherapy will receive pentostatin and cyclophosphamide to prevent an anti-immunotoxin immune response prior to and in conjunction with SS1P immunotoxin therapy.